A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma

Exclusion Criteria

• •History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection
• •Asthma exacerbation within 28 days prior to Visit 1 or during screening (prior to Visit 3)
• •For adults: Active tuberculosis requiring treatment within the 12 months prior to Visit 1
• •For adolescents: History of active tuberculosis requiring treatment
• •Evidence of acute or chronic hepatitis or known liver cirrhosis
• •Known current malignancy or current evaluation for a potential malignancy
• •History of interstitial lung disease, chronic obstructive pulmonary disease, or other clinically significant lung disease other than asthma
• •Infection requiring hospital admission or requiring treatment with intravenous (IV) or intramuscular (IM) antibiotics within 4 weeks prior to Visit 1 or during screening
• •Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening
• •Active parasitic infection or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening
• •Current smoker or former smoker with a smoking history of more than 15 pack-years
• •Current use of an immunomodulatory/ immunosuppressive therapy or past use within 3 months or 5 drug half-lives (whichever is longer) prior to Visit 1
• •Use of a licensed or investigational monoclonal antibody other than anti-interleukin (IL)-13 or anti-IL-4/IL-13, including but not limited to, omalizumab, anti-IL-5, or anti-IL-17, within 6 months or 5 drug half-lives (whichever is longer) prior to Visit 1
• •Receipt of a live attenuated vaccine within the 4 weeks prior to Visit 1 during screening or anticipation of receipt of a live attenuated vaccine throughout the study